RKL Wealth Management LLC Has $3.74 Million Stake in Johnson & Johnson (NYSE:JNJ)

RKL Wealth Management LLC grew its holdings in Johnson & Johnson (NYSE:JNJ) by 2.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 23,883 shares of the company’s stock after buying an additional 482 shares during the period. RKL Wealth Management LLC’s holdings in Johnson & Johnson were worth $3,743,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the business. Moneta Group Investment Advisors LLC lifted its holdings in Johnson & Johnson by 90,144.4% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock worth $9,607,414,000 after purchasing an additional 54,326,454 shares during the last quarter. Norges Bank acquired a new stake in Johnson & Johnson during the 4th quarter worth approximately $4,609,399,000. Morgan Stanley lifted its holdings in Johnson & Johnson by 12.0% during the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock worth $7,458,962,000 after purchasing an additional 4,521,062 shares during the last quarter. Barclays PLC increased its stake in Johnson & Johnson by 61.0% during the 2nd quarter. Barclays PLC now owns 11,287,765 shares of the company’s stock worth $1,868,351,000 after acquiring an additional 4,278,512 shares during the period. Finally, Imprint Wealth LLC increased its stake in Johnson & Johnson by 17,087.7% during the 2nd quarter. Imprint Wealth LLC now owns 2,913,480 shares of the company’s stock worth $291,348,000 after acquiring an additional 2,896,529 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have commented on JNJ. Royal Bank of Canada restated an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, February 28th. Raymond James raised their price objective on Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 3rd. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, March 13th. Finally, Morgan Stanley decreased their price target on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 24th. Seven equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $177.31.

Insider Buying and Selling

In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the transaction, the insider now directly owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the transaction, the insider now directly owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the transaction, the executive vice president now directly owns 141,416 shares in the company, valued at $22,099,078.32. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Trading Down 0.8 %

Shares of JNJ stock opened at $147.57 on Friday. The firm has a market capitalization of $355.61 billion, a P/E ratio of 10.69, a P/E/G ratio of 2.50 and a beta of 0.53. Johnson & Johnson has a twelve month low of $144.95 and a twelve month high of $175.97. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.38. The stock’s fifty day simple moving average is $157.24 and its 200 day simple moving average is $156.00.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 earnings per share for the quarter, topping analysts’ consensus estimates of $2.28 by $0.01. The business had revenue of $21.40 billion for the quarter, compared to analyst estimates of $21.02 billion. Johnson & Johnson had a return on equity of 37.27% and a net margin of 37.79%. Johnson & Johnson’s quarterly revenue was down 9.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.35 EPS. As a group, sell-side analysts predict that Johnson & Johnson will post 10.66 EPS for the current fiscal year.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.